0001628280-21-015950.txt : 20210805
0001628280-21-015950.hdr.sgml : 20210805
20210805180821
ACCESSION NUMBER: 0001628280-21-015950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210803
FILED AS OF DATE: 20210805
DATE AS OF CHANGE: 20210805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lisicki Robert
CENTRAL INDEX KEY: 0001779614
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 211149886
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_162820124726591.xml
FORM 4
X0306
4
2021-08-03
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001779614
Lisicki Robert
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2021-08-03
4
M
0
17500
40.95
A
33601
D
Common Stock
2021-08-03
4
S
0
5605
59.84
D
27996
D
Common Stock
2021-08-03
4
S
0
11895
60.20
D
16101
D
Employee Stock Option (right to buy)
40.95
2021-08-03
4
M
0
17500
0
D
2025-11-26
Common Stock
17500.0
110000
D
The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.74, inclusive.
The options vest over four years, with 25% of the shares subject to the option vesting on November 26, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2021-08-05